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ABSTRACT (224 words) 
CXCL10, a CXC chemokine induced by interferon-gamma [IFN-γ], has been observed in a 
wide variety of chronic inflammatory disorders and autoimmune conditions. Although 
CXCL10 is known to be overexpressed in the salivary glands of individuals with primary 
Sjögren's syndrome (pSS), it is unclear which cells produce CXCL10 under what types of 
stimulations. Here we investigated the precise molecular mechanisms by which CXCL10 was 
produced in human salivary gland ductal (NS-SV-DC) and acinar (NS-SV-AC) cell lines. Our 
results demonstrated that NS-SV-DC cells produced higher levels of CXCL10 compared to 
NS-SV-AC cells. In addition, our findings demonstrated that the regulator of the enhancement 
of CXCL10 was different between NS-SV-DC and NS-SV-AC cells; i.e., interferon-gamma 
(IFN-γ) had more potential than interferon-alpha (IFN-α), tumor necrosis factor (TNF)-α, and 
interleukin (IL)1-β in the induction of CXCL10 production in NS-SV-DC cells, whereas 
TNF-α had potential to induce CXCL10 production in NS-SV-AC cells. A Western blot 
analysis demonstrated that IFN-γ enhanced the production of CXCL10 via both the 
JAK/STAT1 pathway and the NF-κB pathway in NS-SV-DC cells, whereas TNF-α enhanced 
the production of CXCL10 via the NF-κB pathway in NS-SV-AC cells. The results of study 
suggest that the CXCL10 overexpression in the salivary glands is caused mainly by 
IFN-γ-stimulated salivary gland ductal cells. The enhanced production of CXCL10 by IFN-γ 
from ductal cells may result in the inflammation of pSS lesions. 
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INTRODUCTION 
Chemokines are a specialized family of cytokines that function as potent mediators of 
inflammation based on their ability to recruit and activate specific leucocyte subpopulations 
by modifying the expression and affinity status of adhesion molecules on the leucocyte 
surface [1]. CXCL10 is a non-ELR (lacking the Glu-Leu-Arg tripeptide motif) CXC 
chemokine [2]. CXCL9, CXCL10, and CXCL11 utilize the same chemokine receptor, 
CXCR3 [2], a G protein-coupled receptor. CXCR3 is induced on naïve T cells following 
activation, and preferentially remains highly expressed on type-1 helper (Th1)-type CD4+ T 
cells, effector CD8+ T cells, and innate-type lymphocytes, such as natural killer (NK) and 
NKT cells [2]. 
Sjögren's syndrome (SS), one of the most common autoimmune diseases [3], is 
characterized by the eventual total replacement of the acinar structure by marked lymphocytic 
infiltrates in the salivary and lacrimal glands [4]. Histological studies show that CD4+ T cells 
predominantly infiltrate the salivary glands at an early stage of primary SS (pSS) [5]. It has 
been reported that CXCL9, CXCL10, and CXCL11 were involved in the accumulation of 
T-cell infiltrates in the salivary glands of pSS patients [6, 7]. In addition, the inoculation of a 
CXCL10 antagonist into MRL/lpr mice during the early stage of sialadenitis significantly 
reduced the mononuclear cell infiltration and parenchymal destruction [8]. 
Interferons (IFNs) play significant roles in the pathogenesis of autoimmune diseases, 
including SS. IFNs are subdivided into three distinct types: type I IFN (IFN-I; mainly 
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IFN-α/β), type II IFN (IFN-II; mainly IFN-γ), and type III IFN (IFN-III; mainly 
IFN-λ/interleukin [IL]-28/IL-29) [9]. Although the genes involved in SS were originally 
considered to be mediated via only type I interferons, recent findings demonstrated that genes 
upregulated by both type I and type II interferons are involved in pSS [10]. In addition, 
microarray studies in the labial salivary glands (LSGs) of patients with pSS revealed that 
several interferon-regulated genes were up-regulated [11, 12]. Several other cytokines, 
including IL-6, IL-7, IL-10, IL-12, IL-17, IL-21, tumor necrosis factor-alpha (TNF-α) [13], 
and IL-1β [14, 15], have been suggested to play roles in the pathogenesis of pSS. 
It has thus been hypothesized that several cytokines cause autoimmune salivary 
diseases, and that CXCL10 plays an important role in the pathogenesis of SS. However, it is 
not yet known which cells produce CXCL10 by what types of cytokines. To the best of our 
knowledge, no study has evaluated the effects of IFN-α, IFN-γ, or several cytokines on the 
secretion of CXCL9, CXCL10, and CXCL11 by human salivary ductal cells or acinar cells. 
We therefore examined the effects of IFN-α, IFN-γ, TNF-α, and IL-1β stimulation on the 
expressions of CXCL9, CXCL10, and CXCL11 by using immortalized human salivary gland 
cell clones in an in vitro experiment. We also investigated the signal transduction pathways 
that induced the production of CXCL10. 
 
MATERIALS AND METHODS 
Cell culture 
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The characteristics of the cell lines NS-SV-DC (immortalized human salivary gland ductal 
cells) and NS-SV-AC (immortalized human salivary gland acinar cells) are described in detail 
elsewhere [16]. These cell clones were cultured at 37°C in serum-free keratinocyte medium 
(Gibco Laboratories, Gaithersburg, MD) in an incubator with an atmosphere containing 5% 
CO2. 
 
Reagents 
Recombinant human IFN-α, IFN-γ, TNF-α and IL-1β were purchased from R&D Systems 
(Minneapolis, MN). Bay11-7082 was purchased from Wako (Osaka, Japan). 
50-deoxy-50-(methylthio)-adenosine (MTA) was obtained from Sigma-Aldrich Co. (St. Louis, 
MO). Bay11-7082 [17] and MTA [18] were used for the inhibition of nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) and signal transduction and activator 
of transcription1 (STAT1), respectively. 
 
Quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) 
We treated NS-SV-DC and NS-SC-AC cells with 1000 IU/mL IFN-α, 10 ng/mL IFN-γ, 10 
ng/mL TNF-α, and 1 ng/mL IL-1β for 6, 12, or 24 h. Total cellular RNA was isolated with 
TRIzol reagent (Life Technologies, Carlsbad, CA). The cDNA was synthesized from total 
RNA with the use of a PrimeScript RT reagent Kit (Takara, Otsu, Japan). We quantitatively 
analyzed the expression levels of mRNAs for CXCL9, CXCL10, CXCL11 and GAPDH using 
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an ABI Prism 7000 Sequence Detection System (Applied Biosystems Japan, Tokyo) and 
TaqMan® Universal PCR Master Mix (Applied Biosystems) and Assays-on-Demand™ Gene 
Expression Products (Applied Biosystems) according to the manufacturer's recommendations. 
The thermal cycler protocol was 95°C for 10 min, followed by 40 cycles of 95°C for 5 s and 
60°C for 30 s. 
We performed an analysis of the relative gene expression data using the 2−ΔΔCT method 
on Sequence Detection System Software (Applied Biosystems). We calculated the fold 
change in the studied gene expression, normalized to an endogenous control, using the 
formula RQ = 2−ΔΔCT. The relative expression levels of CXCR3 ligand mRNAs are expressed 
as the fold increase in the GAPDH mRNA expression. 
 
Reverse transcription-polymerase chain reaction (RT-PCR) 
The total cellular RNA was isolated from unstimulated NS-SV-DC and NS-SC-DC cells 
using TRIzol reagent. The cDNA was synthesized according to the above method. Specific 
primers were custom synthesized (Sigma, Deisenhofen, Germany). The sense and anti-sense 
primers for IFNGR1, IFNGR2, TNFR1, TNFR2 and GAPDH, respectively, were as follows: 
5’-GCTGTATGCCGAGATGGAAAA-3’ and 5’-AGGAAAATGGCTGGTATGACG-3’, 
5’-CGACAGTAAATGGTTCACGGC-3’ and  
5’-TGGACATAATAACAAAAAAAGGC-3’, 5’-GCCTCTGCCTCAATGGGACCG-3’ and  
5’-GGGGTGAAGCCTGGAGTGGGA-3’, 5’-GCCCACTCGGAACCAGCCACA-3’ and 
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5’-TCAGGCACTCCAAGGGGCAGG-3’, 5’-ACGCATTTGGCTGTATTGGG-3’ and 
5’-TGATTTTGGAGGGATCTCGC-3’. The PCR reactions were conducted in a DNA 
Thermal Cycler (model LifeECO, Nippon Genetics, Tokyo). The reaction conditions were as 
follows: IFNGR1, after 1 min of denaturation at 94°C, 35 cycles of PCR were performed 
(94°C for 30 s and 68°C for 6 min), followed by a final 6 min extension at 68°C; IFNGR2, 
TNFR1, TNFR2, and GAPDH: after 1 min of denaturation at 94°C, 35 cycles of PCR were 
performed (94°C for 30 s and 68°C for 3 min), followed by a final 3 min extension at 68°C. 
The amplified products were electrophoresed in ethidium bromide-stained 1.5% agarose gel. 
 
Enzyme-linked immunosorbent assay (ELISA) 
We treated NS-SV-DC and NS-SC-AC cells with 1000 IU/mL IFN-α, 10 ng/mL IFN-γ, 10 
ng/mL TNF-α, and 1 ng/mL IL-1β for 6, 12, or 24 h. The concentrations of CXCL9, CXCL10, 
and CXCL11were each determined with commercially available ELISA kits (R&D Systems) 
according to the manufacturer's instructions. Optimal absorbance was read at 450 nm in a 
microtiter plate reader. The CXCR3 ligand protein levels were determined using the standard 
curve prepared for each assay. 
We performed blocking experiments using specific transcription factors. NS-SV-DC 
cells were incubated with IFN-γ (10 ng/mL) in the presence or absence of the STAT1 
inhibitor, MTA (1 mM), or the NF-κB inhibitor, Bay11-7082 (10 µM), for 24 h. NS-SV-AC 
cells were incubated with TNF-α (10 ng/mL) in the presence or absence of Bay11-7082 (10 
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µM) or MTA (1 mM) for 24 h. CXCL10 secretion was analyzed by ELISA kits. Optimal 
absorbance was read at 450 nm in a microtiter plate reader. 
 
Protein isolation and Western blot analysis 
NS-SV-DC cells were treated with 10 ng/mL IFN-γ for 1, 5, 10, 30, 60, 120, or 360 min, and 
NS-SV-AC cells were treated with 10 ng/mL TNF-α for 5, 15, 30, 60, or 120 min. Whole-cell 
lysates were prepared using M-PER lysis solution (Thermo Fisher Scientific, Waltham, MA) 
supplemented with HaltTM Protease Inhibitor Cocktail (Thermo Fisher Scientific). Nuclear 
extracts were prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagent (Thermo 
Fisher Scientific). Cytosolic extracts (20 μg) were subjected to electrophoresis on 10% 
sodium dodecyl sulfate (SDS)-polyacrylamide gels (Bio-Rad, Hercules, CA), and then 
transferred onto nitrocellulose membranes. The membranes were blocked with 3% bovine 
serum albumin and incubated with each of the following antibodies (all from Cell Signaling 
Technology, Beverly, MA; diluted at 1:1000): anti-janus kinase1 (JAK1), anti-Phospho-JAK1, 
anti-JAK2, anti-Phospho-JAK2, anti-STAT1, anti- Phospho-STAT1, anti-p65, anti-inhibitor of 
κB (IκB)-α, anti-Phospho-IκB-α, and anti-β-actin. After intervening rinses with TBS-T, the 
IgG secondary antibodies (Cell Signaling Technology; diluted at 1:1000) were used for the 
respective primary antibodies. The immune complexes were visualized by enhanced 
chemiluminescence (ECL) Western Blotting Detection Reagent (GE Healthcare, 
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Buckinghamshire, UK). The density of the visualized immune complexes was digitized using 
an Amersham Imager 600 (GE Healthcare). 
 
Statistical analysis 
The data were analyzed with the use of the non-parametric Mann-Whitney U-test. SPSS 
Statistics-15.0 J software was used for the analyses. Statistical tests were two-sided, and 
significance was defined as a p-value <0.05. 
 
RESULTS 
The expressions of CXCL9, CXCL10, and CXCL11 mRNA and protein following IFN-α, 
IFN-γ, TNF-α, or IL-1β stimulation in NS-SV-DC and NS-SV-AC cells 
We attempted to identify the factors that regulate the expressions of CXCL9, CXCL10, and 
CXCL11, using NS-SV-DC and NS-SV-AC cells. The CXCL10 gene has been reported to 
contain response elements for STAT1 and NF-κB [19]. We therefore selected IFN-α, IFN-γ, 
TNF-α, and IL-1β. Indeed, these cytokines were reported to be associated with pSS [10, 13–
15]. We conducted a qRT-PCR to examine the expression levels of CXCL9, CXCL10, and 
CXCL10 mRNAs following IFN-α, IFN-γ, TNF-α, or IL-1β stimulation. As shown in Figure 
1a, significant increases in the expressions of CXCL9, CXCL10, and CXCL11 mRNAs were 
observed in NS-SV-DC cells after treatment with IFN-γ compared to the unstimulated control 
cells. At 12 h of treatment, the mRNA levels of CXCL9, CXCL10, and CXCL11 were 
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24352.8-, 3026.4-, and 712.5-fold higher than the basal levels, respectively. In the case of 
TNF-α treatment, an increase in the expression of CXCL10 mRNA was detected only in 
NS-SV-AC cells (Fig. 1a). On the other hand, IFN-α had a marginal effect on the expression 
of only CXCL11 mRNAs in NS-SV-DC cells, and no effect in NS-SV-AC cells. IL-1β had no 
effect on the expression of these CXCR3 ligand mRNAs in either cell line (Fig. 1a). 
To further evaluate the expressions of CXCL9, CXCL10, and CXCL11 proteins, we 
detected the protein levels by ELISA using the conditioned medium derived from NS-SV-DC 
and NS-SV-AC cells treated with IFN-α, IFN-γ, TNF-α, or IL-1β. The NS-SV-DC cells 
showed a significantly increased expression of the CXCL10 proteins after IFN-γ stimulation 
(Fig. 1b). The NS-SV-AC cells showed an increase in the expression of CXCL10 proteins 
after TNF-α stimulation (Fig. 1b). IFN-α and IL-1β had no significant effect on the 
expressions of these CXCR3 ligand proteins in either cell line (Fig. 1b). These results indicate 
that ductal cells play an important role in the secretion of CXCR3 ligand chemokines, 
especially CXCL10, in salivary gland cells. In addition, our findings demonstrated that IFN-γ 
and TNF-α are the key cytokines in CXCL10 production in salivary gland cells. 
 
The detection of IFN-γ receptor and TNF-α receptor mRNA in NS-SV-DC and 
NS-SV-AC cells 
NS-SV-DC and NS-SV-AC cells were examined for the presence of mRNA for IFN-γ 
receptor (IFNGR) and TNF-α receptor (TNFR). IFNGR consists of two subunits: IFNGR1 
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(also known as the IFN-γ receptor α chain) and IFNGR2 (also known as the IFN-γ receptor β 
chain) [20]. TNFR consists of two subunits: a 55 kDa type1 receptor (TNFR1) and a 75 kDa 
type2 receptor (TNFR2) [21]. As shown in Figure 2, NS-SV-DC and NS-SV-AC cells 
expressed the mRNAs for IFNGR1, IFNGR2, TNFR1 and TNFR2 almost same at the intense 
level in both cells.  
 
The effect of IFN-γ on the CXCL10 production in NS-SV-DC cells and the effect of 
TNF-α on CXCL10 production in NS-SV-AC cells 
We next conducted an ELISA assay to investigate the effect by the density of cytokines on the 
CXCL10 production in each cell line. As shown in Figure 3a, the CXCL10 production in 
NS-SV-DC cells was increased by the treatment with IFN-γ in a dose-dependent manner. 
Although the CXCL10 production in NS-SV-AC cells was increased by the treatment with 
TNF-α (>10 ng/mL), there was no dose-dependent increase (Fig. 3b). These results suggested 
that NS-SV-DC cells had a greater ability to produce CXCL10 compared to NS-SV-AC cells. 
 
The involvement of STAT1 and NF-κB in CXCL10 production in NS-SV-DC and 
NS-SV-AC cells 
The CXCL10 gene has been reported to contain response elements for STAT1 and NF-κB 
[19]. Accordingly, we next examined the involvement of the two transcription factors STAT1 
and NF-κB in the production of CXCL10. We did this by using a STAT1 inhibitor, MTA [18], 
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and an NF-κB inhibitor, Bay11-7082 [17]. As shown in Figure 4a, the addition of MTA (1 
mM) resulted in a significant decrease in the IFN-γ-induced CXCL10 production in 
NS-SV-DC cells (p<0.05). Bay11-7082 also significantly decreased the IFN-γ-induced 
CXCL10 secretion (p<0.05) (Fig. 4a). In contrast, the TNF-α-induced CXCL10 production in 
NS-SV-AC cells was significantly reduced by Bay11-7082 (p<0.05) but not by MTA (Fig. 
4b). These data suggest that in NS-SV-DC cells, IFN-γ enhanced the CXCL10 production via 
both the JAK/STAT1 pathway and the NF-κB pathway, whereas in N S-SV-AC cells, TNF-α 
enhanced the CXCL10 production via the NF-κB pathway but not the JAK/STAT1 pathway. 
 
IFN-γ promoted the phosphorylations of JAK1, STAT1, and IκB-α in NS-SV-DC cells, 
whereas TNF-α promoted the phosphorylation of IκB-α in NS-SV-AC cells. 
To clarify the signal transduction pathway activated by IFN-γ in NS-SV-DC cells, we 
examined the expression levels of JAK1, JAK2, STAT1, phospho-JAK1, phospho-JAK2, 
phospho-STAT1, p65, IκB-α, and phospho-IκB-α. The Western blot analysis demonstrated 
that IFN-γ induced the phosphorylations of JAK2 and STAT1 (Fig. 5a); however, JAK1 was 
not observed in NS-SV-DC cells (data not shown). In addition, IFN-γ promoted the 
phosphorylation of IκB-α, and p65 was shifted to the nucleus in NS-SV-DC cells (Fig. 5b). 
We then investigated the signal transduction pathway activated by TNF-α in 
NS-SV-AC cells. The expression levels of p65, IκB-α, and phospho-IκB-α were examined. 
The Western blot analysis showed that IκB-α was degraded by TNF-α, and p65 was shifted to 
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the nucleus in NS-SV-AC cells (Fig. 5c). These results indicate that IFN-γ promotes the 
phosphorylation of JAK2 and IκB-α, thereby resulting in the activation of both the 
JAK/STAT1 pathway and the NF-κB pathway in NS-SV-DC cells, whereas TNF-α promotes 
the phosphorylation of IκB-α, thereby resulting in the activation of the NF-κB pathway in 
NS-SV-AC cells. 
 
DISCUSSION 
SS is a chronic autoimmune disease characterized by lymphocytic infiltration and the 
destruction of salivary and lacrimal glands [3, 4]. Histologically, SS is characterized by an 
extensive target tissue infiltration of Th cells, predominantly CD4+ Th cells but also CD8+ Th 
cells [5]. Based on the expression patterns of cytokines, it has been shown that CD4+ Th cells 
are distributed in Th1 and Th2 cells. Accumulated evidence indicates a close relationship 
between the cytokine expression in salivary gland tissues and the development and 
progression of pSS. There is supportive evidence that leukocyte activation and elicitation 
through a cytokine-driven network is one of the key processes in the autoimmune response 
[22]. A 2001 review indicated that chemokines are one of the families of effector molecules 
under the control of the cytokine-driven network [22]. 
Chemokines are a superfamily of cytokines that regulate immune cell migration under 
both inflammatory and normal physiological conditions [23]. The interactions between 
chemokines and their receptors play important roles in the induction of a selective local 
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infiltration of specific cells in various diseases [24]. The CXCR3 ligand chemokines (CXCL9, 
CXCL10, and CXCL11) are dual-function chemokines induced by IFN-γ, and they are 
produced during Th1-type immune responses [2] by diverse cell types, including neutrophils, 
monocytes, fibroblasts, keratinocytes, endothelial cells, and astrocytes [25]. 
The expression of CXCR3 and CXCR3 targeting chemokines has been demonstrated to 
be involved in several diseases and pathological states, including sarcoidosis, viral infections, 
allograft rejection, rheumatoid arthritis, diabetes, and glomerulonephritis [26–29]. Regarding 
SS, it was reported that CXCR3 ligand chemokines were expressed in the salivary glands of 
pSS [6, 7], and that the downregulation of CXCL10 reduced the mononuclear cell infiltration 
in MRL/lpr mice [8]. Although CXCR3 ligand chemokines and CXCR3 appear to contribute 
to the pathogenesis of pSS, the clinical significance of chemokines and their receptors and the 
underlying molecular mechanisms are not yet known. 
In the present study, we performed an in vitro experiment using NS-SV-DC and 
NS-SV-AC cells to identify the precise molecular mechanism involved in the regulation of 
CXCL9, CXCL10, and CXCL11 in salivary gland cells. We selected IFN-α, IFN-γ, TNF-α, 
and IL-1β as reagents that may regulate the expression of CXCR3 ligands. The CXCL10 gene 
has been reported to contain NF-κB and STAT1-responsible elements in the promoter regions 
[19]. Interestingly, our study demonstrated that the regulator of the enhancement of CXCR3 
ligand chemokines was different between NS-SV-DC and NS-SV-AC cells. Although both 
cells expressed IFN-γ receptor and TNF-α receptor, we detected a significant increase in the 
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expression of CXCL10 in NS-SV-DC cells after IFN-γ treatment, whereas the increase in the 
expression of CXCL10 in NS-SC-AC cells was detected after TNF-α treatment. These results 
indicated that IFN-γ and TNF-α are the key cytokines in CXCL10 production in salivary 
gland cells. Our findings also demonstrated that NS-SV-DC cells had a greater ability to 
produce CXCL10 compared to NS-SV-AC cells. These findings are in accord with the 
histopathological images of pSS that show the periductal infiltration of T cells. The CXCL10 
secretion from ductal cells by IFN-γ stimulation may be caused by an infiltration of CXCR3+ 
T cells in pSS lesion. 
The blocking experiments using specific transcription factors revealed that a specific 
inhibitor of the STAT1 pathway (MTA) decreased the CXCL10 in IFN-γ-treated NS-SC-DC 
cells. The specific inhibitor of the NF-κB pathway (Bay11-7082) also decreased the CXCL10 
in IFN-γ-treated NS-SV-DC cells. These results are consistent with those of a study reporting 
that IFN-γ potentiates the TNF-α-induced CXCL10 production in human monocytes by 
increasing the activation of STAT1 and NF-κB through the JAK1 and JAK2 pathways (i.e., 
by crosstalk between IFN-γ and TNF-α signal transduction) [30]. In contrast, the specific 
inhibitor of the NF-κB pathway (Bay11-7082) but not the specific inhibitor of the STAT1 
pathway (MTA) decreased the CXCL10 in TNF-α-treated NS-SV-AC cells. Our findings 
demonstrated that the IFN-γ-induced CXCL10 expression was mediated by the JAK2/STAT1 
and NF-κB pathways in NS-SV-DC cells, whereas the TNF-α-induced CXCL10 expression 
was transduced by the NF-κB pathway in NS-SV-AC cells. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 17 
 
In conclusion, the results of this study demonstrated that the regulator of the 
enhancement of CXCL10 was different between salivary ductal cells and acinar cells, and that 
salivary ductal cells had a higher ability to produce CXCL10 compared to acinar cells. The 
enhanced production of CXCL10 by IFN-γ from ductal cells may result in the migration of 
CXCR3+ T cells. This may be one of the key processes in the inflammation of pSS lesions. 
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FIGURE LEGENDS 
Fig. 1. The expressions of CXCL9, CXCL10, and CXCL11 mRNA and protein following 
IFN-α, IFN-γ, TNF-α or IL-1β stimulation in NS-SV-DC and NS-SV-AC cells. a: 
NS-SV-DC and NS-SC-AC cells were treated with IFN-α (1000 IU/mL), IFN-γ (10 ng/mL), 
TNF-α (10 ng/mL) or IL-1β (1 ng/mL) for 6, 12, or 24 h. Total RNAs were prepared, and the 
quantification of mRNA levels was evaluated by qRT-PCR. Unstimulated cells were used as a 
control. Bar: mean±SD. b: NS-SV-DC and NS-SC-AC cells were treated with IFN-α (1000 
IU/mL), IFN-γ (10 ng/mL), TNF-α (10 ng/mL) or IL-1β (1 ng/mL) for 6, 12, or 24 h. An 
ELISA was performed to measure CXCL9, CXCL10, and CXCL11 protein in the conditioned 
medium. Unstimulated cells were used as a control. Bar: mean±SD. 
 
Fig. 2. The detection of IFN-γ receptor and TNF-α receptor mRNA in NS-SV-DC and 
NS-SV-AC cells. NS-SV-DC and NS-SV-AC cells were examined for the presence of 
mRNAs for IFNGR1, IFNGR2, TNFR1, and TNFR2 by RT-PCR. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as housekeeping gene. The 
mRNAs of IFN-γ receptor and TNF-α receptor were detected in both cells. 
 
Fig. 3. The effect of IFN-γ on the CXCL10 production in NS-SV-DC cells and the effect 
of TNF-α on the CXCL10 production in NS-SV-AC cells. a: NS-SV-DC cells were treated 
with 1, 10, 50, or 100 ng/ml of IFN-γ for 24 h. An ELISA was performed to measure 
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CXCL10 protein in the conditioned medium. Bar: mean±SD. *p<0.05. b: NS-SV-AC cells 
were treated with 1, 10, 50, or 100 ng/ml of TNF-α for 24 h. An ELISA was performed to 
measure CXCL10 protein in the conditioned medium. Bar: mean±SD. *p<0.05. 
 
Fig. 4. The involvement of STAT1 and NF-κB in the CXCL10 production in NS-SV-DC 
and NS-SV-AC cells. a: NS-SV-DC cells were incubated with IFN-γ (10 ng/mL) in the 
presence or absence of the STAT1 inhibitor MTA (1 mM) or the NF-κB inhibitor Bay11-7082 
(10 µM) for 24 h. CXCL10 secretion was analyzed with ELISA kits. Optimal absorbance was 
read at 450 nm in a microtiter plate reader. The IFN-γ-induced CXCL10 production in 
NS-SV-DC cells was significantly reduced by Bay11-7082 and MTA. Bar: mean±SD. 
*p<0.05. b: NS-SV-AC cells were incubated with TNF-α (10 ng/mL) in the presence or 
absence of Bay11-7082 (10 µM) or MTA (1 mM) for 24 h. The TNF-α-induced CXCL10 
production in NS-SV-AC cells was significantly reduced by Bay11-7082, but not by MTA. 
CXCL10 secretion was analyzed with ELISA kits. Optimal absorbance was read at 450 nm in 
a microtiter plate reader. Bar: mean±SD. *p<0.05. ND: not determined. 
 
Fig. 5. IFN-γ promoted the phosphorylations of JAK1, STAT1, and IκB-α in NS-SV-DC 
cells, whereas TNF-α promoted the phosphorylation of IκB-α in NS-SV-AC cells. a: 
NS-SV-DC cells were treated with 10 ng/mL of IFN-γ. The Western blot analysis showed that 
phospho-JAK2 and phospho-STAT1 were significantly increased after IFN-γ stimulation. b: 
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NS-SV-DC cells were treated with 10 ng/mL of IFN-γ. IFN-γ promoted the phosphorylation 
of IκB-α, and p65 was shifted to the nucleus in NS-SV-DCcells. c: NS-SV-AC cells were 
treated with 10 ng/mL of TNF-α. The Western blot analysis showed that IκB-α was degraded 
by TNF-α, and p65 was shifted to the nucleus in NS-SV-AC cells. 
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